Saving money is wise, but investing is profitable
In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Sana Biotechnology (SANA) FINANCIAL RESULTS FOR SECOND QUARTER 2022.

05.08.2022

Non-GAAP net loss per share for the second quarter of 2022 was -0.47 dollars.  
 
Cash and cash equivalents as of June 30, 2022 were $579.6 million compared to $746.9 million as of December 31, 2021.